Relvar Ellipta

Relvar Ellipta Adverse Reactions

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Full Prescribing Info
Adverse Reactions
Summary of the safety profile: Data from large asthma and COPD clinical trials were used to determine the frequency of adverse reactions associated with fluticasone furoate/vilanterol. In the asthma clinical development program a total of 7,034 patients were included in an integrated assessment of adverse reactions.
In the COPD clinical development programme a total of 6,237 subjects were included in an integrated assessment of adverse reactions.The most commonly reported adverse reactions with fluticasone furoate and vilanterol were headache and nasopharyngitis. With the exception of pneumonia and fractures, the safety profile was similar in patients with asthma and COPD. During clinical studies, pneumonia and fractures were more frequently commonly observed in patients with COPD.
Tabulated list of adverse reactions: Adverse reactions are listed by system organ class and frequency. The following convention has been used for the classification of frequencies: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. (See Table 3.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: *Pneumonia (see Precautions): In an integrated analysis of the two replicate one year studies in COPD (mean post-bronchodilator screening FEV1 45% of predicted, standard deviation (SD) 13%) with an exacerbation in the preceding year (n = 3255), the number of pneumonia events per 1000 patient years was 97.9 with FF/VI 200/25, 85.7 in the FF/VI 100/25 and 42.3 in the VI 25 group. For severe pneumonia the corresponding number of events per 1000 patient years were 33.6, 35.5, and 7.6 respectively, while for serious pneumonia the corresponding events per 1000 patient years were 35.1 for FF/VI 200/25, 42.9 with FF/VI 100/25, 12.1 with VI 25. Finally, the exposure-adjusted cases of fatal pneumonia were 8.8 for FF/VI 200/25 versus 1.5 for FF/VI 100/25 and 0 for VI 25.
In SUMMIT, a multi-centre, randomised study (HZC113782), 16,568 subjects received fluticasone furoate/vilanterol 100/25 micrograms, fluticasone furoate 100 micrograms, vilanterol 25 micrograms, or placebo for a mean of 1.7 years. Subjects had moderate COPD (mean post-bronchodilator screening FEV1 60% of predicted, SD 6%) and a history of, or an increased risk of, cardiovascular disease. The adverse events of pneumonia are noted in the table as follows. (See Table 4.)

Click on icon to see table/diagram/image

In an integrated analysis of 11 studies in asthma (7,034 patients), the incidence of pneumonia per 1000 patient years was 18.4 for FF/VI 200/25 versus 9.6 for FF/VI 100/25 and 8.0 in the placebo group.
**Cardiovascular events (see Precautions): For the SUMMIT study, cardiovascular adverse events are noted in the table as follows. (See Table 5.)

Click on icon to see table/diagram/image

***Fractures: In two replicate 12 month studies in a total of 3,255 patients with COPD the incidence of bone fractures overall was low in all treatment groups, with a higher incidence in all Relvar Ellipta groups (2%) compared with the vilanterol 25 micrograms group (<1%). Although there were more fractures in the Relvar Ellipta groups compared with the vilanterol 25 micrograms group, fractures typically associated with corticosteroid use (e.g., spinal compression/thoracolumbar vertebral fractures, hip and acetabular fractures) occurred in <1% of the Relvar Ellipta and vilanterol treatment arms.
For the SUMMIT study, fractures are noted in the table as follows. (See Table 6.)

Click on icon to see table/diagram/image

In an integrated analysis of 11 studies in asthma (7,034 patients), the incidence of fractures was <1%, and usually associated with trauma.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the National Centre for Adverse Drug Reaction Monitoring, National Pharmaceutical Regulatory Agency (NPRA).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in